SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Abgenix, Inc. (ABGX)

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: bob zagorin4/18/2005 11:05:21 AM
   of 590
 
Abgenix to Host Conference Call on First Quarter 2005 Financial Results
Monday April 18, 6:30 am ET

FREMONT, Calif., April 18 /PRNewswire-FirstCall/ -- Abgenix, Inc. (Nasdaq: ABGX - News) will hold a conference call on Tuesday, April 26, 2005 at 1:30 p.m. PT, 4:30 p.m. ET, to discuss first quarter financial results and to provide an update on the company's antibody discovery, development, and manufacturing activities. Bill Ringo, president and chief executive officer of Abgenix, will host the call.

ADVERTISEMENT
To participate in the teleconference, please dial 800-761-0748 fifteen minutes before the conference begins. International callers should dial 617-614-2706. The pass code is 89600730. The call will also be webcast live at www.abgenix.com. A replay of the call will be available until May 10, 2005 on the company's website or by dialing 888-286-8010. International callers should dial 617-801-6888. The replay participant code is 86920645.

About Abgenix

Abgenix is a biopharmaceutical company focused on the discovery, development and manufacturing of human therapeutic antibodies. The company's antibody development platform includes a leading technology and state-of-the-art manufacturing capabilities that enable the rapid generation, selection and production of high affinity, fully human antibody product candidates to a variety of disease targets. Abgenix leverages its leadership position in human antibody technology to build a diversified product portfolio through its own development efforts and the establishment of collaborations with multiple pharmaceutical and biotechnology companies. For more information on Abgenix, visit the company's website at www.abgenix.com.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext